Akari Therapeutics, Plc (AKTX) is a Biotechnology company in the Healthcare sector, currently trading at $4.63. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is AKTX = $30 (+547.9% upside).
Valuation: AKTX trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Net income is $17M (loss), growing at -42.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $754,000 against $28M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 0.44 (tight liquidity). Debt-to-assets is 1.6%. Total assets: $48M.
Analyst outlook: 6 / 8 analysts rate AKTX as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).
